Veru needs additional cash for fresh trial of respiratory distress drug

Veru knows the route that its once-dismissed respiratory distress drug has to take to pacify regulators, but the biotech needs some more cash to hit the road.

That’s according to the company’s latest earnings report, in which Veru said that, despite having clear guidance from the FDA on sabizabulin’s potential approval path, it will seek grants, partnerships and “similar sources” of cash to fund further development. Without an assist, Veru does not expect to advance the asset into a phase 3 study.